Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Mirum Pharmaceuticals, Inc. (MIRM) has a Wall Street consensus price target of $114.20, based on estimates from 18 covering analysts. With the stock currently trading at $92.29, this represents a potential upside of +23.7%. The company has a market capitalization of $4.79B.
Analyst price targets range from a low of $95.00 to a high of $140.00, representing a 39% spread in expectations. The median target of $114.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MIRM trades at a trailing P/E of -196.4x. Analysts expect EPS to grow -229.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how MIRM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for MIRM is $114.2, representing 23.7% upside from the current price of $92.29. With 18 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MIRM has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $114.2 implies 23.7% upside from current levels.
MIRM's current price is $92.29 with a consensus target of $114.2 (23.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $140 for MIRM, while the most conservative target is $95. The consensus of $114.2 represents the median expectation. These targets typically reflect 12-month expectations.
MIRM is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 17 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MIRM stock forecast based on 18 Wall Street analysts shows a consensus price target of $114.2, with estimates ranging from $95 (bear case) to $140 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MIRM, with a "Buy" consensus rating and $114.2 price target (23.7% upside). 18 of 18 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MIRM analyst price targets range from $95 to $140, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $114.2 consensus represents the middle ground.